Investigating how a decoy receptor affects immune cells and tumor growth
Official title: The role of decoy receptor IL-1R2 in Treg biology and anti-tumor immunity
Funded at University of California, San Francisco · NIH-10991656 · Data updated 2026-11-12
This study is looking at how a specific protein called IL-1R2 affects certain immune cells that help control the body's response to tumors, and it aims to find ways to boost the immune system's ability to fight cancer by understanding these interactions better.
Quick facts
| Grant type | Fellowship grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California, San Francisco NIH-funded |
| Lab location | 1 site (San Francisco, United States) |
| Project start | July 1, 2023 |
| Project end | June 30, 2025 |
| Funding year | 2024 |
| Award (this year) | $53,974 |
| NIH project number | 5F31CA278371-02 |
| Project ID | NIH-10991656 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals with cancers that may be influenced by immune regulation, particularly those with high levels of inflammation.
✕Less likely to help
Patients with non-cancerous conditions or those whose tumors do not involve immune regulation may not benefit from this research.
What this research studies
This research explores the role of the decoy receptor IL-1R2 in regulating immune cells known as regulatory T cells (Tregs) and their impact on tumor immunity. By analyzing samples from both healthy and cancerous tissues, the study aims to understand how IL-1R2 influences Treg activation and its potential effects on tumor growth. The researchers will utilize advanced techniques like RNA sequencing to identify changes in Treg behavior and their relationship with tumor development. This work could provide insights into how to enhance anti-tumor immunity through modulation of Treg activity.
Why it matters
Potential benefit: If successful, this research could lead to new strategies for improving cancer treatment by enhancing the body's immune response against tumors.
How similar studies have gone: Previous research has shown that targeting IL-1 signaling can significantly reduce tumor incidence, indicating a promising avenue for further exploration.
Where this research is happening
-
University of California, San Francisco
San Francisco, United States Active
Researchers
- Principal investigator: Habrylo, Ireneusz — University of California, San Francisco
- Study coordinator: Habrylo, Ireneusz
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.